BACKGROUND: The human immunodeficiency virus type 1 (HIV-1) epidemic is associated with a significant increase in the incidence of tuberculosis (TB); however, little is known about the quality of Mycobacterium tuberculosis (MTB)-specific cellular immune responses in coinfected individuals. METHODS: A total of 137 HIV-1-positive individuals in Durban, South Africa, were screened with the use of overlapping peptides spanning Ag85A, culture filtrate protein 10 (CFP-10), early secretory antigen target 6 (ESAT-6), and TB10.4, in an interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay. Intracellular cytokine staining for MTB-specific production of IFN-gamma, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-2 was performed, as was ex vivo phenotyping of memory markers on MTB-specific T cells. RESULTS: A total of 41% of subjects responded to ESAT-6 and/or CFP-10, indicating the presence of latent MTB infection. The proportion of MTB-specific IFN-gamma(+)/TNF-alpha(+) CD4(+) cells was significantly higher than the proportion of IFN-gamma(+)/IL-2(+) CD4(+) cells (P = .0220), and the proportion of MTB-specific IL-2-secreting CD4 cells was inversely correlated with the HIV-1 load (P = .0098). MTB-specific CD8 T cells were predominately IFN-gamma(+)/TNF-alpha(+)/IL-2(-). Ex vivo memory phenotyping of MTB-specific CD4 and CD8 T cells indicated an early to intermediate differentiated phenotype for the population of effector memory cells. CONCLUSIONS: Polyfunctional MTB-specific CD4 and CD8 T cell responses are maintained in the peripheral blood of HIV-1-positive individuals, in the absence of active disease, and the functional capacity of these responses is affected by HIV-1 disease status.
BACKGROUND: The human immunodeficiency virus type 1 (HIV-1) epidemic is associated with a significant increase in the incidence of tuberculosis (TB); however, little is known about the quality of Mycobacterium tuberculosis (MTB)-specific cellular immune responses in coinfected individuals. METHODS: A total of 137 HIV-1-positive individuals in Durban, South Africa, were screened with the use of overlapping peptides spanning Ag85A, culture filtrate protein 10 (CFP-10), early secretory antigen target 6 (ESAT-6), and TB10.4, in an interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay. Intracellular cytokine staining for MTB-specific production of IFN-gamma, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-2 was performed, as was ex vivo phenotyping of memory markers on MTB-specific T cells. RESULTS: A total of 41% of subjects responded to ESAT-6 and/or CFP-10, indicating the presence of latent MTB infection. The proportion of MTB-specific IFN-gamma(+)/TNF-alpha(+) CD4(+) cells was significantly higher than the proportion of IFN-gamma(+)/IL-2(+) CD4(+) cells (P = .0220), and the proportion of MTB-specific IL-2-secreting CD4 cells was inversely correlated with the HIV-1 load (P = .0098). MTB-specific CD8 T cells were predominately IFN-gamma(+)/TNF-alpha(+)/IL-2(-). Ex vivo memory phenotyping of MTB-specific CD4 and CD8 T cells indicated an early to intermediate differentiated phenotype for the population of effector memory cells. CONCLUSIONS: Polyfunctional MTB-specific CD4 and CD8 T cell responses are maintained in the peripheral blood of HIV-1-positive individuals, in the absence of active disease, and the functional capacity of these responses is affected by HIV-1 disease status.
Authors: Keertan Dheda; Ajit Lalvani; Robert F Miller; Geoff Scott; Helen Booth; Margaret A Johnson; Alimuddin Zumla; Graham Aw Rook Journal: AIDS Date: 2005-11-18 Impact factor: 4.177
Authors: E Jouanguy; F Altare; S Lamhamedi; P Revy; J F Emile; M Newport; M Levin; S Blanche; E Seboun; A Fischer; J L Casanova Journal: N Engl J Med Date: 1996-12-26 Impact factor: 91.245
Authors: Annie F Luetkemeyer; Edwin D Charlebois; Laura L Flores; David R Bangsberg; Steven G Deeks; Jeffrey N Martin; Diane V Havlir Journal: Am J Respir Crit Care Med Date: 2007-01-11 Impact factor: 21.405
Authors: A Geluk; K E van Meijgaarden; K L Franken; J W Drijfhout; S D'Souza; A Necker; K Huygen; T H Ottenhoff Journal: J Immunol Date: 2000-12-01 Impact factor: 5.422
Authors: Homayoun Shams; Peter Klucar; Steven E Weis; Ajit Lalvani; Patrick K Moonan; Hassan Safi; Benjamin Wizel; Katie Ewer; Gerald T Nepom; David M Lewinsohn; Peter Andersen; Peter F Barnes Journal: J Immunol Date: 2004-08-01 Impact factor: 5.422
Authors: Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones Journal: Nat Med Date: 2002-04 Impact factor: 53.440
Authors: N Pavan Kumar; R Anuradha; R Suresh; R Ganesh; Janani Shankar; V Kumaraswami; Thomas B Nutman; Subash Babu Journal: Clin Vaccine Immunol Date: 2011-09-28
Authors: Samuel M Behar; Stephen M Carpenter; Matthew G Booty; Daniel L Barber; Pushpa Jayaraman Journal: Semin Immunol Date: 2014-10-11 Impact factor: 11.130
Authors: Kaustuv Nayak; Lichen Jing; Ronnie M Russell; D Huw Davies; Gary Hermanson; Douglas M Molina; Xiaowu Liang; David R Sherman; William W Kwok; Junbao Yang; John Kenneth; Syed F Ahamed; Anmol Chandele; Kaja Murali-Krishna; David M Koelle Journal: Tuberculosis (Edinb) Date: 2015-03-27 Impact factor: 3.131
Authors: Chetan Seshadri; Lin Lin; Thomas J Scriba; Glenna Peterson; David Freidrich; Nicole Frahm; Stephen C DeRosa; D Branch Moody; Jacques Prandi; Martine Gilleron; Hassan Mahomed; Wenxin Jiang; Greg Finak; Willem A Hanekom; Raphael Gottardo; M Juliana McElrath; Thomas R Hawn Journal: J Immunol Date: 2015-10-14 Impact factor: 5.422
Authors: I Sauzullo; R Scrivo; F Mengoni; A Ermocida; M Coppola; G Valesini; V Vullo; C M Mastroianni Journal: Clin Exp Immunol Date: 2014-06 Impact factor: 4.330
Authors: Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Fatima Isaacs; Alana Keyser; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Anthony Hawkridge; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Helen McShane; Willem A Hanekom Journal: Eur J Immunol Date: 2010-01 Impact factor: 5.532